ACM
MRNS

Atika Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Atika Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-32,250
Closed -$869K – 81
2017
Q3 		$758K Buy
+32,250
New +$362K 0.22% 75

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Atika Capital Management's MRNS Position: Q4 2017 in Review

Atika Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2017, closing a stake of 32,250 shares — an estimated $869K sold.

Atika Capital Management first reported a position in MRNS in Q3 2017 and held it in 1 quarter. The position peaked at $758K in Q3 2017. 65 funds tracked by Wall St. Rank hold MRNS as of Q4 2017.

  • Atika Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • Atika Capital Management sold 32,250 Marinus Pharmaceuticals, Inc shares in Q4 2017, an estimated $869K.
  • Atika Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 1 quarter.
  • Atika Capital Management's Marinus Pharmaceuticals, Inc position peaked at $758K in Q3 2017.
  • 65 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2017.

Based on Atika Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.